<i>Ad hoc</i> Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline <i>BRCA</i> Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects-Reference-Cited by-同舟云学术

Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects

Published:2022-11-15 Issue:11 Volume:2 Page:1436-1444
ISSN:2767-9764
Container-title:Cancer Research Communications
language:en
Short-container-title:

Author:

Mirza Mansoor Raza¹,Lindahl Gabriel²,Mahner Sven³^ORCID,Redondo Andrés⁴,Fabbro Michel⁵^ORCID,Rimel Bobbie J.⁶,Herrstedt Jørn⁷,Oza Amit M.⁸^ORCID,Canzler Ulrich⁹¹⁰,Berek Jonathan S.¹¹,González-Martín Antonio¹²^ORCID,Follana Phillipe¹³^ORCID,Lord Rosemary¹⁴,Azodi Masoud¹⁵,Estenson Kasey¹⁶,Wang Zebin¹⁷,Li Yong¹⁷,Gupta Divya¹⁸,Matulonis Ursula¹⁹²⁰^ORCID,Feng Bin¹⁸^ORCID

Affiliation:

1. 1Nordic Society of Gynaecological Oncology (NSGO) and Department of Oncology Rigshospitalet–Copenhagen University Hospital, Copenhagen, Denmark.

2. 2Nordic Society of Gynaecological Oncology (NSGO) and Department of Oncology, Linköping University Hospital, Linköping, Sweden.

3. 3Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe (AGO) and Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

4. 4Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Department of Medical Oncology, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.

5. 5ICM Val d'Aurelle Parc Euromedecine, Oncologie Médicale, Montpellier, GINECO, Paris, France.

6. 6Cedars-Sinai Cancer, Cedars-Sinai Medical Center, Los Angeles, California.

7. 7Department of Clinical Oncology and Palliative Care Zealand University Hospital Roskilde and Næstved, University of Copenhagen, Copenhagen, Denmark.

8. 8Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

9. 9Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe (AGO) and Department of Gynecology and Obstetrics, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

10. 10National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.

11. 11Stanford University School of Medicine and Stanford Cancer Institute, Stanford, California.

12. 12Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Program in Solid Tumors, Center for Applied Medical Research (CIMA), Pamplona, Spain, Grupo Español de Investigación en Cáncer de Ovario (GEICO), Madrid, Spain.

13. 13Centre Antoine Lacassagne, Nice, France.

14. 14Medical Oncology, Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, United Kingdom.

15. 15Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, Connecticut.

16. 16GSK, Philadelphia, Pennsylvania.

17. 17GSK, Waltham, Massachusetts.

18. 18GSK, Waltham, Massachusetts.

19. 19Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

20. 20Harvard Medical School, Boston, Massachusetts.

Abstract

In this analysis, we examined the relationship between progression-free survival (PFS) and mutation status of 18 homologous recombination repair (HRR) genes in patients in the non-germline BRCA-mutated (non-gBRCAm) cohort of the ENGOT-OV16/NOVA trial (NCT01847274), which evaluated niraparib maintenance therapy for patients with recurrent ovarian cancer. This post hoc exploratory biomarker analysis was performed using tumor samples collected from 331 patients enrolled in the phase III ENGOT-OV16/NOVA trial's non-gBRCAm cohort. Niraparib demonstrated PFS benefit in patients with either somatic BRCA-mutated (sBRCAm; HR, 0.27; 95% confidence interval, CI, 0.08–0.88) or BRCA wild-type (BRCAwt; HR, 0.47; 95% CI, 0.34–0.64) tumors. Patients with BRCAwt tumors with other non-BRCA HRR mutations also derived benefit from niraparib (HR, 0.31; 95% CI, 0.13–0.77), as did patients with BRCAwt/HRRwt (HRR wild-type) tumors (HR, 0.49; 95% CI, 0.35–0.70). When patients with BRCAwt/HRRwt tumors were further categorized by genomic instability score (GIS), clinical benefit was observed in patients with homologous recombination–deficient (GIS ≥ 42; HR, 0.33; 95% CI, 0.18–0.61) and in patients with homologous recombination–proficient (HRp; GIS < 42; HR, 0.60; 95% CI, 0.36–0.99) disease. Although patients with sBRCAm, other non-BRCA HRR mutations, or GIS ≥ 42 benefited the most from niraparib treatment, PFS benefit was also seen in HRp (GIS < 42) patients without HRR mutations. These results support the use of niraparib in patients with recurrent ovarian cancer regardless of BRCA/HRR mutation status or myChoice CDx GIS. Significance: We retrospectively evaluated the mutational profile of HRR genes in tumor samples from 331 patients from the non-germline BRCA-mutated cohort of the phase III NOVA trial of patients with platinum-sensitive high-grade serous ovarian cancer. Patients with non-BRCA HRR mutations generally benefited from second-line maintenance treatment with niraparib compared with placebo.

Publisher

American Association for Cancer Research (AACR)

Link

https://aacrjournals.org/cancerrescommun/article-pdf/doi/10.1158/2767-9764.CRC-22-0240/3219145/crc-22-0240.pdf

Reference28 articles.

1. Trial watch — inhibiting PARP enzymes for anticancer therapy;Sistigu;Mol Cell Oncol,2016

2. Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy;Walsh;Gynecol Oncol,2015

3. Links between genome integrity and BRCA1 tumor suppression;Li;Trends Biochem Sci,2012

4. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer;Ledermann;N Eng J Med,2012

5. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2;Oza;Gynecol Oncol,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene;Genetics in Medicine;2024-10

2. Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?;Molecular Diagnosis & Therapy;2024-07-05

3. Genomic Features of Homologous Recombination Deficiency in Breast Cancer: Impact on Testing and Immunotherapy;Genes;2024-01-26

4. Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?;Cancers;2023-01-25